Difference between revisions of "Zanubrutinib (Brukinsa)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
|||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. |
| − | ==Diseases for which it is established | + | ==Diseases for which it is established== |
| + | *[[Chronic lymphocytic leukemia]] | ||
*[[Waldenström macroglobulinemia]] | *[[Waldenström macroglobulinemia]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Follicular lymphoma]] |
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
*[[Marginal zone lymphoma]] | *[[Marginal zone lymphoma]] | ||
| Line 17: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| + | ===[[Chronic lymphocytic leukemia]]=== | ||
| + | *2023-01-19: Approved for [[Chronic lymphocytic leukemia|chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)]]. ''(Based on SEQUOIA<sub>CLL</sub>)'' | ||
| + | ===[[Follicular lymphoma]]=== | ||
| + | *2024-03-07: Granted accelerated approval with obinutuzumab for relapsed or refractory [[Follicular lymphoma|follicular lymphoma (FL)]] after two or more lines of systemic therapy. ''(Based on ROSEWOOD)'' | ||
===[[Mantle cell lymphoma]]=== | ===[[Mantle cell lymphoma]]=== | ||
| − | *11 | + | *2019-11-14: Accelerated approval for adult patients with [[mantle cell lymphoma|mantle cell lymphoma (MCL)]] who have received at least one prior therapy. ''(Based on BGB-3111-AU-003 & BGB-3111-206)'' |
===[[Marginal zone lymphoma]]=== | ===[[Marginal zone lymphoma]]=== | ||
| − | * | + | *2021-09-14: Accelerated approval for adult patients with relapsed or refractory [[Marginal zone lymphoma|marginal zone lymphoma (MZL)]] who have received at least one [[Regimen_classes#Anti-CD20-based_regimen|anti-CD20-based regimen]]. ''(Based on MAGNOLIA and BGB-3111-AU-003)'' |
===[[Waldenström macroglobulinemia]]=== | ===[[Waldenström macroglobulinemia]]=== | ||
| − | * | + | *2021-08-31: Approved for adult patients with [[Waldenström macroglobulinemia|Waldenström’s macroglobulinemia (WM)]]. ''(Based on ASPEN)'' |
| + | ==History of changes in EMA indication== | ||
| + | ===[[Chronic lymphocytic leukemia]]=== | ||
| + | *2022-11-15: Extension of indication to include treatment of adult patients with [[Chronic lymphocytic leukemia|chronic lymphocytic leukaemia (CLL)]]. ''(Based on SEQUOIA<sub>CLL</sub> & ALPINE)'' | ||
| + | ===[[Follicular lymphoma]]=== | ||
| + | *2023-10-12: CHMP approved new indication in combination with obinutuzumab for the treatment of adult patients with refractory or relapsed [[follicular lymphoma|follicular lymphoma (FL)]] who have received at least two prior systemic therapies. | ||
| + | ===[[Marginal zone lymphoma]]=== | ||
| + | *2022-10-28: Extension of indication to include treatment of adult patients with [[Marginal zone lymphoma|marginal zone lymphoma (MZL)]] who have received at least one-prior anti-CD20-based therapy. ''(Based on BGB-3111-AU-003 & MAGNOLIA)'' | ||
| + | ===[[Waldenström macroglobulinemia]]=== | ||
| + | *2021-11-22: Initial authorization as monotherapy for the treatment of adult patients with [[Waldenström macroglobulinemia|Waldenström’s macroglobulinaemia (WM)]] who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. ''(Based on ASPEN)'' | ||
==Also known as== | ==Also known as== | ||
| Line 39: | Line 53: | ||
[[Category:Chronic lymphocytic leukemia medications]] | [[Category:Chronic lymphocytic leukemia medications]] | ||
| + | [[Category:Follicular lymphoma medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Marginal zone lymphoma medications]] | [[Category:Marginal zone lymphoma medications]] | ||
| Line 44: | Line 59: | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
| + | [[Category:EMA approved in 2021]] | ||
Latest revision as of 00:14, 6 July 2024
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
Diseases for which it is established
Diseases for which it is used
Patient drug information
History of changes in FDA indication
Chronic lymphocytic leukemia
- 2023-01-19: Approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (Based on SEQUOIACLL)
Follicular lymphoma
- 2024-03-07: Granted accelerated approval with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (Based on ROSEWOOD)
Mantle cell lymphoma
- 2019-11-14: Accelerated approval for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. (Based on BGB-3111-AU-003 & BGB-3111-206)
Marginal zone lymphoma
- 2021-09-14: Accelerated approval for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. (Based on MAGNOLIA and BGB-3111-AU-003)
Waldenström macroglobulinemia
- 2021-08-31: Approved for adult patients with Waldenström’s macroglobulinemia (WM). (Based on ASPEN)
History of changes in EMA indication
Chronic lymphocytic leukemia
- 2022-11-15: Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL). (Based on SEQUOIACLL & ALPINE)
Follicular lymphoma
- 2023-10-12: CHMP approved new indication in combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Marginal zone lymphoma
- 2022-10-28: Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy. (Based on BGB-3111-AU-003 & MAGNOLIA)
Waldenström macroglobulinemia
- 2021-11-22: Initial authorization as monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. (Based on ASPEN)
Also known as
- Code name: BGB-3111
- Brand name: Brukinsa